Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Cue Biopharma (CUE – Research Report) today and set a price target of $7.00. The company’s shares closed yesterday at $3.62.
According to TipRanks, Tenthoff is a 5-star analyst with an average return of 12.0% and a 41.68% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Cue Biopharma, and Crispr Therapeutics AG.
Currently, the analyst consensus on Cue Biopharma is a Strong Buy with an average price target of $10.00, which is a 176.24% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $15.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $5.12 and a one-year low of $2.18. Currently, Cue Biopharma has an average volume of 457.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.
Read More on CUE:
